Surge In Partnerships And Licensing In China Highlights Need For Greater Flexibility
This article was originally published in PharmAsia News
As cross-border deals rise rapidly and finding new partners becomes harder in China, multinational drug makers must be flexible in their deal strategies. Seasoned executives from AstraZeneca, Bayer, Merck and Chinese startup Ascletis offer insights on what to look for in a dynamic market.
You may also be interested in...
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.